Fresenius Kabi raises outlook for 2012

Fresenius Kabi has raised its expectations for the 2012 business year based on its better-than-expected performance during the first few months of the year.

Parent company Fresenius announced during a capital market day event that the business unit is now expected to achieve organic sales growth of between seven and nine percent this year, up from the previous forecast of six to eight percent.

So far this year, Fresenius Kabi has seen substantial growth across all of its operating regions and product segments, greatly exceeding earlier forecasts, particularly in the US.

This is being driven by high demand for high-quality intravenous generic drugs, as well as major growth in emerging market healthcare spending.

Rainer Baule, chief executive officer (CEO) of Fresenius Kabi, said: "A high level of vertical integration and technological leadership in many areas provide us a highly competitive cost position, in turn leading to strong market positions. Fresenius Kabi is excellently positioned for further profitable growth."

Earlier this year, it was announced that Mats Henriksson will take over as CEO of Fresenius Kabi on January 1st 2013 as the successor to the retiring Mr Baule.